search button

PT93, a novel caffeic acid amide derivative, suppresses glioblastoma cells migration, proliferation and MMP-2/-9 expression

  • Authors:
    • Kaishu Li
    • Yalin Tu
    • Qingyu Liu
    • Ying Ouyang
    • Mingliang He
    • Ming Luo
    • Jingkao Chen
    • Rongbiao Pi
    • Anmin Liu

  • View Affiliations

  • Published online on: February 1, 2017     https://doi.org/10.3892/ol.2017.5663
  • Pages: 1990-1996
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastoma multiforme (GBM) is the most malignant type of primary brain tumor in adults and can diffusely infiltrate adjacent normal tissue. GBM is therefore rarely cured by surgery or radiation therapy. Matrix metalloproteinases (MMPs) are involved in tissue remodeling and numerous other physiological progresses. The MMPs MMP‑2 and MMP‑9 are associated with the invasion ability of GBM. PT93 is a novel caffeic acid amide derivative that was first synthesized in 2013. In the present study, the human GBM T98G, U87 and U251 cell lines and the normal mouse neuron HT22 cell line were used to investigate the anticancer and cytotoxic effects of PT93 in vitro. The cytotoxicity of PT93 was measured using MTT and lactate dehydrogenase assays. The anti‑proliferation effect was tested using a cell colony formation assay. Gelatin zymography analysis and a scratch test were used to investigate the anti‑migration mechanism of PT93. Western blot analysis was used to measure the expression of MMP‑2/‑9. The experimental results showed that PT93 suppressed the proliferation of T98G cells, and showed cytotoxicity effects at high concentration in T98G, U87, U251 and HT22 cell lines. Furthermore, PT93 limited the migration ability of the cells and inhibited the extracellular MMP‑2 and MMP‑9 activity of T98G and U251 cells. Finally, the present study confirmed that PT93 affects the level of MMP‑2/‑9 expression in T98G cells in a concentration‑dependent manner. The present study indicates that PT93, as a novel caffeic acid amide derivative, may be used in the treatment of GBM.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li K, Tu Y, Liu Q, Ouyang Y, He M, Luo M, Chen J, Pi R and Liu A: PT93, a novel caffeic acid amide derivative, suppresses glioblastoma cells migration, proliferation and MMP-2/-9 expression. Oncol Lett 13: 1990-1996, 2017
APA
Li, K., Tu, Y., Liu, Q., Ouyang, Y., He, M., Luo, M. ... Liu, A. (2017). PT93, a novel caffeic acid amide derivative, suppresses glioblastoma cells migration, proliferation and MMP-2/-9 expression. Oncology Letters, 13, 1990-1996. https://doi.org/10.3892/ol.2017.5663
MLA
Li, K., Tu, Y., Liu, Q., Ouyang, Y., He, M., Luo, M., Chen, J., Pi, R., Liu, A."PT93, a novel caffeic acid amide derivative, suppresses glioblastoma cells migration, proliferation and MMP-2/-9 expression". Oncology Letters 13.3 (2017): 1990-1996.
Chicago
Li, K., Tu, Y., Liu, Q., Ouyang, Y., He, M., Luo, M., Chen, J., Pi, R., Liu, A."PT93, a novel caffeic acid amide derivative, suppresses glioblastoma cells migration, proliferation and MMP-2/-9 expression". Oncology Letters 13, no. 3 (2017): 1990-1996. https://doi.org/10.3892/ol.2017.5663